Merck & Co., Inc.
2000 Galloping Hill Road
About Merck & Co., Inc.
For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola.
Founder: George Merck
CEO: Kenneth Frazier
CFO: Robert Davis
Please click here for Merck job opportunities.
Please click here for clinical trial information.
Tweets by Merck
2532 articles with Merck & Co., Inc.
4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours
4D pharma plc is a clinical stage biopharmaceutical company, pioneering the development of Live Biotherapeutic Products
Merck & Co’s anti-PD-1 therapy Keytruda dazzled in its pivotal Phase III KEYNOTE-407 trial.
Merck(NYSE:MRK), today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock.
BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®
Anti-PD-1 therapy KEYTRUDA® (pembrolizumab) is a potential new treatment regimen for advanced lung cancer.
ImmunoGen, released positive efficacy and tolerability data from its FORWARD II trial of its mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer (EOC). Shares jumped almost 12 percent in premarket trading.
Genentech's Late-Stage Trial Data Shows Combination of Tecentriq and Avastin Helps NSCLC Patients...
3/26/2018Genentech is planning to seek regulatory approval for a blended lung cancer treatment following positive interim results from a late-stage trial that showed a combination of Tecentriq and Avastin plus chemotherapy enabled patients to live longer.
IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer
IO Biotech announces it has entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), through a subsidiary, focused on the clinical evaluation of IO102 with KEYTRUDA® (pembrolizumab) in patients with non-small cell lung cancer (NSCLC).
Ferring Pharmaceuticals and MSD Announce Completion of Largest Clinical Trial Ever Conducted in Postpartum Haemorrhage
The CHAMPION trial is assessing the effectiveness and safety of heat-stable carbetocin vs. oxytocin, the current standard of care, for preventing PPH after vaginal birth
Government officials say they are now certain they know who launched the NotPetya cyberwar that slammed operations at Merck last year.
AstraZeneca and Merck announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).
Alzheimer's drug development took another hit.
The 60-year-old chemist has been charged with stealing 219.79 grams of potassium cyanide from a Merck facility in Pennsylvania.
Parkinson’s Institute and Clinical Center Collaborates with Merck to Evaluate LRRK2 Kinase Inhibition in Preclinical Model of Parkinson’s Disease
The Parkinson’s Institute and Clinical Center has entered into a collaboration with Merck, known as MSD outside the United States and Canada, to study the effects of LRRK2 kinase inhibitors on non-motor symptoms in a preclinical model of gastrointestinal (GI) dysfunction in Parkinson’s disease.
Worldwide sales were $10.4 billion for the fourth quarter of 2017, an increase of 3 percent compared with the fourth quarter of 2016, including a 1 percent positive impact from foreign exchange.
Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.
Prokaryotics Announces Licensing Agreement With Merck for Novel Investigational Antibiotic Candidates
Specific terms of the agreement were not disclosed.
Mr. Thulin will stand for election with the company’s other directors in connection with Merck’s Annual Meeting of Shareholders on May 22, 2018.
Marshall co-founded more than a decade ago, and which was acquired by Sosei in 2015.
Merck today announced that the Board of Directors has declared a quarterly dividend of $0.48 per share of the company’s common stock for the second quarter of 2018.
First-Time Data for Merck’s KEYTRUDA (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium
Merck today announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA (pembrolizumab).